Illumina, Inc. (ILMN)

In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.

SAN JOSE, Calif.--(BUSINESS WIRE)-- #NGS--Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.

At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to combine more than one omic insight reveals unprecedented biological depth and knowledge, all of which is streamlined by Illumina Connected Multiomics for multimodal data analysis.

TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology" SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaS eq X systems , advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 billion reads (35B).

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Illumina, Inc. (NASDAQ: ILMN - Get Free Report) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 8,300,465 shares, an increase of 28.6% from the January 15th total of 6,455,325 shares. Approximately 5.4% of the shares of the stock are short sold. Based on

Eagle Health Investments LP lowered its stake in shares of Illumina, Inc. (NASDAQ: ILMN) by 6.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 322,261 shares of the life sciences company's stock after selling 21,100 shares during the quarter. Illumina comprises approximately

SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference TD Cowen 46th Annual Health Care Conference 2026 on March 3, 2026 The fireside chat is scheduled for 12:10pm PT (3:10pm ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.

Caprock Group LLC purchased a new position in Illumina, Inc. (NASDAQ: ILMN) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm purchased 14,794 shares of the life sciences company's stock, valued at approximately $1,479,000. Several other hedge funds have also recently bought and sold shares of

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago.